Status
Conditions
Treatments
About
Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of Ertugliflozin and Sitagliptin Con-initiation in patients with Type II Diabetes Mellitus in the Pakistani population. The study duration will be 12 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Hussain Abidi, MBBS; Asima Khan, MBBS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal